Qiagen (NYSE: QGEN)
Qiagen Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Qiagen Company Info
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
News & Analysis
Thermo Fisher Increases Its Buyout Price for Qiagen, but Investors Ask for More
Will Thermo Fisher be able to complete its deal to acquire Qiagen, or will shareholders vote it down?
Here's How Qiagen Trounced Q1 Estimates
The molecular diagnostics company blew past Wall Street's top- and bottom-line expectations in the first quarter for one main reason.
Coronavirus Test-makers Ramp Up Production
Multiple companies have gained regulatory approvals in recent days.
Will COVID-19 Derail New Drugs?
Disruptions in clinical trials and delayed regulatory decisions could slow the rate of new drug approvals.
FDA Warns About Potential Supply Chain Issues for Coronavirus Tests
There's no shortage yet, but the FDA is working to address supply issues with a key component of COVID-19 diagnostics tests.
Here's Why Qiagen Jumped Higher Today
The diagnostic-test maker is being acquired for $11.5 billion.
Stock Market News: Tilray Comes Down; Thermo Fisher Makes a Big Buy
The stock market was turbulent Tuesday morning.
Thermo Fisher Scientific to Spend $11.5 Billion Upgrading Its DNA Testing Game
The world's leading provider of scientific tools will buy QIAGEN and its growing menu of molecular diagnostic products.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.